Collegium Pharmaceutical, Inc. Operating Cash Flow
Collegium Pharmaceutical, Inc. (COLL) reported Operating Cash Flow of $128.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $71.32M, a 1.54% decline year-over-year.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $57.11M, a 3.10% increase year-over-year.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $123.05M, a 45.37% increase year-over-year.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $78.44M.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $329.32M, a 60.66% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $204.98M, a 25.39% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $274.75M, a 121.16% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $124.23M, a 19.96% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $128.44M 10-Q · filed 2026-08-06 | $251.48M derived: sum of 3 quarters · filed 2026-08-06 | $329.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $57.11M 10-Q · filed 2026-05-07 | $180.16M derived: sum of 2 quarters · filed 2026-05-07 | $258.60M derived: sum of 3 quarters · filed 2026-05-07 | $331.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $123.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $201.49M derived: sum of 2 quarters · filed 2026-02-26 | $273.93M derived: sum of 3 quarters · filed 2026-08-06 | $329.32M 10-K · filed 2026-02-26 |
| 2025-09-30 | $78.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $150.88M derived: sum of 2 quarters · filed 2026-08-06 | $206.28M 10-Q · filed 2025-11-06 | $290.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $72.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $127.84M 10-Q · filed 2026-08-06 | $212.48M derived: sum of 3 quarters · filed 2026-08-06 | $203.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $55.40M 10-Q · filed 2026-05-07 | $140.04M derived: sum of 2 quarters · filed 2026-05-07 | $131.04M derived: sum of 3 quarters · filed 2026-05-07 | $198.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $84.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.64M derived: sum of 2 quarters · filed 2026-02-26 | $143.04M derived: sum of 3 quarters · filed 2026-02-26 | $204.98M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $58.40M derived: sum of 2 quarters · filed 2025-11-06 | $120.34M 10-Q · filed 2025-11-06 | $193.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $67.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $129.34M 10-Q · filed 2025-08-07 | $202.67M derived: sum of 3 quarters · filed 2026-02-26 | $276.69M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $61.94M 10-Q · filed 2025-05-08 | $135.28M derived: sum of 2 quarters · filed 2026-02-26 | $209.29M derived: sum of 3 quarters · filed 2026-02-26 | $309.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $73.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $147.36M derived: sum of 2 quarters · filed 2026-02-26 | $247.08M derived: sum of 3 quarters · filed 2026-02-26 | $274.75M 10-K · filed 2026-02-26 |
| 2023-09-30 | $74.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $173.74M derived: sum of 2 quarters · filed 2024-11-07 | $201.41M 10-Q · filed 2024-11-07 | $267.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $99.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $127.39M 10-Q · filed 2024-08-08 | $193.72M derived: sum of 3 quarters · filed 2025-02-27 | $236.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $27.67M 10-Q · filed 2024-05-09 | $94.00M derived: sum of 2 quarters · filed 2025-02-27 | $136.76M derived: sum of 3 quarters · filed 2025-02-27 | $177.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $66.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $109.09M derived: sum of 2 quarters · filed 2025-02-27 | $149.54M derived: sum of 3 quarters · filed 2025-02-27 | $124.23M 10-K · filed 2025-02-27 |
| 2022-09-30 | $42.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $83.22M derived: sum of 2 quarters · filed 2023-11-07 | $57.91M 10-Q · filed 2023-11-07 | $94.10M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $40.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $15.14M 10-Q · filed 2023-08-03 | $51.33M derived: sum of 3 quarters · filed 2024-02-22 | $68.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$25.32M 10-Q · filed 2023-05-04 | $10.88M derived: sum of 2 quarters · filed 2024-02-22 | $28.14M derived: sum of 3 quarters · filed 2024-02-22 | $57.67M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $36.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $53.45M derived: sum of 2 quarters · filed 2024-02-22 | $82.99M derived: sum of 3 quarters · filed 2024-02-22 | $103.56M 10-K · filed 2024-02-22 |
| 2021-09-30 | $17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $46.79M derived: sum of 2 quarters · filed 2022-11-03 | $67.36M 10-Q · filed 2022-11-03 | $89.94M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $29.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $50.10M 10-Q · filed 2022-08-04 | $72.68M derived: sum of 3 quarters · filed 2023-02-23 | $106.86M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $20.57M 10-Q · filed 2022-05-10 | $43.15M derived: sum of 2 quarters · filed 2023-02-23 | $77.33M derived: sum of 3 quarters · filed 2023-02-23 | $121.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $22.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $56.76M derived: sum of 2 quarters · filed 2023-02-23 | $100.61M derived: sum of 3 quarters · filed 2023-02-23 | $93.94M 10-K · filed 2023-02-23 |
| 2020-09-30 | $34.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $78.03M derived: sum of 2 quarters · filed 2021-11-04 | $71.36M 10-Q · filed 2021-11-04 | $87.02M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $43.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $37.19M 10-Q · filed 2021-08-05 | $52.84M derived: sum of 3 quarters · filed 2022-02-24 | $58.91M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$6.67M 10-Q · filed 2021-05-06 | $8.99M derived: sum of 2 quarters · filed 2022-02-24 | $15.06M derived: sum of 3 quarters · filed 2022-02-24 | $29.68M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $21.73M derived: sum of 2 quarters · filed 2022-02-24 | $36.35M derived: sum of 3 quarters · filed 2022-02-24 | $27.78M 10-K · filed 2022-02-24 |
| 2019-09-30 | $6.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $20.70M derived: sum of 2 quarters · filed 2020-11-05 | $12.13M 10-Q · filed 2020-11-05 | $54.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $14.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $6.06M 10-Q · filed 2020-08-05 | $48.35M derived: sum of 3 quarters · filed 2021-02-25 | $90.18M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$8.57M 10-Q · filed 2020-05-07 | $33.72M derived: sum of 2 quarters · filed 2021-02-25 | $75.55M derived: sum of 3 quarters · filed 2021-02-25 | $131.16M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $42.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $84.12M derived: sum of 2 quarters · filed 2021-02-25 | $139.73M derived: sum of 3 quarters · filed 2021-02-25 | $169.39M 10-K · filed 2021-02-25 |
| 2018-09-30 | $41.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $97.44M derived: sum of 2 quarters · filed 2019-11-06 | $127.10M 10-Q · filed 2019-11-06 | $113.81M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $55.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $85.27M 10-Q · filed 2019-08-07 | $71.97M derived: sum of 3 quarters · filed 2020-02-27 | $59.41M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $29.66M 10-Q · filed 2019-05-08 | $16.37M derived: sum of 2 quarters · filed 2020-02-27 | $3.80M derived: sum of 3 quarters · filed 2020-02-27 | -$13.67M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$13.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$25.86M derived: sum of 2 quarters · filed 2020-02-27 | -$43.33M derived: sum of 3 quarters · filed 2020-02-27 | -$67.02M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$12.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$30.03M derived: sum of 2 quarters · filed 2018-11-08 | -$53.72M 10-Q · filed 2018-11-08 | -$77.01M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$17.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$41.16M 10-Q · filed 2018-08-08 | -$64.44M derived: sum of 3 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$23.69M 10-Q · filed 2018-05-09 | -$46.98M derived: sum of 2 quarters · filed 2019-02-27 | ||
| 2016-12-31 | -$23.29M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$75.05M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | -$51.77M 10-Q · filed 2017-11-08 | |||
| 2015-12-31 | -$21.57M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |